High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza

Influenza Clinical Trial

Official title:

High-Dose Versus Standard-Dose Oseltamivir for the Treatment of Severe Influenza and Avian Influenza: A Phase II Double-Blind, Randomized Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00298233
• Other study ID #: SEA 001
• Secondary ID: N01A050042
• Status: Completed
• Phase: Phase 2
• First received: March 1, 2006
• Last updated: May 26, 2014
• Start date: February 2006
• Est. completion date: January 2010

Study information

• Verified date: May 2014
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Influenza, also known as the flu, is a contagious respiratory illness caused by influenza viruses. The illness can range in severity, from mild to severe to even death, and it causes an estimated 500,000 to 1,000,000 deaths worldwide each year. In the last several years, there have been increasing numbers of human cases of avian influenza, or bird flu. This trend may pose a threat of a future pandemic--worldwide outbreak of disease--with an avian influenza virus that can easily spread from person to person. Oseltamivir is an antiviral medication that is used to treat people with uncomplicated human influenza, and it may be effective in treating people with either severe human influenza or avian influenza. The purpose of this international study is to compare standard-dose oseltamivir versus high-dose oseltamivir for treating people who are hospitalized with severe human influenza or avian influenza.

Description:

Two main types of influenza virus--Types A and B--are responsible for the seasonal flu epidemics that occur each year. The influenza A viruses can be broken down into subtypes based on two proteins on the surface of the virus: hemagglutinin (H) and neuraminidase (N). The A subtypes usually found in humans are H1N1, H1N2, and H3N2. Other A subtypes are found primarily in animals. For example, the "avian influenza virus" refers to an influenza A virus that is found chiefly in birds.

Although avian influenza does not usually affect humans, increasing numbers of cases of human infection from avian influenza virus H5N1 have been reported in the last several years. Because all influenza viruses have the ability to modify, there is concern that this trend of increasing cases may pose a threat of a future pandemic with a new H5N1 virus that could spread easily from person to person.

The H5N1 virus that has caused human infection in Asia is resistant to amantadine and rimantadine, two antiviral medications commonly used for treating people with influenza. Another antiviral medication, oseltamivir, is currently used to treat people with uncomplicated human influenza. The purpose of this study is to compare standard-dose oseltamivir and high-does oseltamivir for treating people who are hospitalized with severe human influenza or avian influenza. The study will also attempt to identify how severe human influenza and avian influenza differ in the following factors: clinical manifestation, relationship between antiviral plasma concentrations and viral dynamics, and pathogenesis.

Upon meeting certain screening criteria, participants will be randomly assigned to receive oseltamivir either at a standard-dose level (75 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function) or at a high-dose level (150 mg twice daily orally or equivalent dose adjusted for age, weight, and kidney function). Treatment will continue for 5 days, after which participants who meet clinical failure criteria will continue their assigned treatment for an additional 5 days. It is anticipated that participants will remain hospitalized through the course of treatment. On Day 0, which marks the first day of hospitalization, participants will undergo a medical review, physical examination, blood sampling, nasal swab, throat swab, anal swab, and chest x-ray. An endotracheal aspirate procedure and urine sampling may also be performed. During the hospital stay, most of the above procedures will be repeated regularly, and additional samples of lung fluid, cerebral spinal fluid, and pleural fluid may be obtained. On Day 5 and possibly on Day 10, participants will undergo a follow-up x-ray. If applicable, participants will attend outpatient study visits on Days 10, 14, and 28 for further evaluation; participants with avian influenza will also attend visits on Days 56 and 180.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 326
• Est. completion date: January 2010
• Est. primary completion date: January 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 1 Year and older

Eligibility

Inclusion Criteria:

• At least one of the following respiratory symptoms: cough, dyspnea, sore throat

• Evidence of severe influenza or avian influenza, as defined below

• Severe influenza infection criteria:

1. Need for hospitalization

2. One of the following:

1. New infiltrate on chest x-ray (or any infiltrate if no prior chest x-ray or not known)

2. Severe tachypnea (more information on this criterion can be found in the protocol)

3. Severe dyspnea

4. Arterial oxygen saturation of 92% or less on room air by trans-cutaneous method

3. Positive diagnostic testing for influenza, as defined by either rapid influenza antigen (Ag) positive (A or B) or qualitative reverse transcriptase-polymerase chain reaction (RT-PCR) positive for any influenza

4. Illness (defined by onset of fever, respiratory symptoms, or constitutional symptoms) began within 10 days before study enrollment

• Avian influenza infection criteria:

1. Nasal wash, nasopharyngeal aspirate, endotracheal aspirate, nasal swab, or throat swab that is RT-PCR positive influenza for H5 influenza

2. Illness (defined by onset of fever, respiratory symptoms, or constitutional symptoms) began within 14 days before study enrollment

Exclusion Criteria:

• Received more than 72 hours of oseltamivir (six doses) within 14 days

• Received oseltamivir at higher than standard doses within the last 14 days or during current acute illness, whichever is longer

• History of allergy or severe intolerance of oseltamivir, as determined by the investigator

• Alternate explanation for the clinical findings, as determined by the investigator and with the information immediately available

• Creatine clearance less than 10 ml/minute

• Pregnant or breastfeeding

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Avian Influenza
• Influenza
• Influenza, Human
• Severe Influenza

Intervention

Drug:
• Oseltamivir
Oseltamivir is a sialic acid analogue that potently and specifically inhibits the viral neuraminidases by competitively and reversibly interacting with the active enzyme site of influenza A and B viruses. Oseltamivir will be administered orally in standard formulations (capsules for adults and children at least 15 years of age; suspension for children younger than 15 years).

Locations

Country	Name	City	State
Singapore	Changi General Hospital	Singapore
Singapore	National University Hospital, National University of Singapore	Singapore
Singapore	Tan Tock Seng Hospital	Singapore
Thailand	Queen Sirikit National Institute of Child Health	Bangkok
Thailand	Siriraj Hospital Mahidol University	Bangkok
Thailand	Bamrasnaradura Infectious Disease Institute	Nonthaburi
Thailand	Chest Disease Institute	Nonthaburi
Vietnam	National Hospital of Pediatrics	Hanoi
Vietnam	National Institute fof Infectious and Tropical Diseases	Hanoi
Vietnam	Children's Hospital #1	Ho Chi Minh City
Vietnam	Hospital for Tropical Diseases	Ho Chi Minh City
Vietnam	Pediatric Hospital #2	Ho Chi Minh City

Sponsors (4)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)	University of Oxford, Wellcome Trust, World Health Organization

Countries where clinical trial is conducted

Singapore,  Thailand,  Vietnam, 

References & Publications (4)

Colman PM. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci. 1994 Oct;3(10):1687-96. Review. — View Citation

de Jong MD, Bach VC, Phan TQ, Vo MH, Tran TT, Nguyen BH, Beld M, Le TP, Truong HK, Nguyen VV, Tran TH, Do QH, Farrar J. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med. 2005 Feb 17;352(7):686-91. — View Citation

Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis. 1995 Jan-Mar;1(1):7-15. Review. — View Citation

South East Asia Infectious Disease Clinical Research Network. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ. 2013 May — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of All Participants Negative for Viral RNA on Day 5	Proportion of all participants with no detectable viral RNA by reverse transcriptase-polymerase chain reaction (RT-PCR) in a combined nasal and throat swab sample on day 5.	After 5 days of treatment	No
Secondary	Participants Meeting Criteria for Day 5 Clinical Failure	Proportion of participants that have clinical failure by day 5. Subjects that meet one of the following on Day 5 will be classified as a clinical failure: Severe tachypnea (respiratory rate = 30 for ages =12 years, rate = 40 for ages 6 to 12 years, rate =45 for ages 3 to 6 years, rate = 50 for ages 1 to 3 years); Severe dyspnea (unable to speak full sentences, or use of accessory respiratory muscles); Arterial oxygen saturation =92% on room air by trans-cutaneous method; Need for mechanical ventilation or intensive care unit (ICU) admission For the purpose of endpoint definition, death prior to or on Day 5 will also be considered a clinical failure at Day 5.	After 5 days of treatment	No
Secondary	In-hospital Mortality Rates	Standard therapy with oseltamivir is five days. Those patients with persistent symptoms on day five were continued on the randomized dose for an additional five days and assessments were performed up to day 10.	After up to 10 days of treatment	No
Secondary	Median Time (Days) Receipt of Oxygen		Throughout study, 14 days	No
Secondary	Median Time (Days) in ICU		Throughout study, 14 days	No
Secondary	Median Time (Days) on Ventilation	Use of mechanical ventilation at any time for subjects with severe influenza and avian influenza.	Throughout study, 14 days	No

External Links

•   South East Asian Infectious Diseases Clinical Research Network - Protocol and support documents available